The Technical Analyst
Ampio Pharmaceuticals Inc [AMPE]
Exchange: AMEX Industry: Biotechnology
Ampio Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.79% $0.285
America/New_York / 10 mai 2024 @ 10:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.237 mill |
| EPS: | -11.70 |
| P/E: | -0.0200 |
| Earnings Date: | Mar 26, 2024 |
| SharesOutstanding: | 0.832 mill |
| Avg Daily Volume: | 0.0563 mill |
| RATING 2024-05-10 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0200 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.102 - 0.468 ( +/- 64.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-09 | Buchi J Kevin | Buy | 21 858 | Common Stock |
| 2023-06-08 | Buchi J Kevin | Buy | 25 000 | Common Stock |
| 2023-05-24 | Martino Michael A | Buy | 76 890 | Common Stock |
| 2023-05-16 | Buchi J Kevin | Buy | 32 534 | Common Stock |
| 2023-05-15 | Buchi J Kevin | Buy | 44 026 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 6 813 241 | Sell: 1 519 396 |
Forecast:
11:51 - $0.312
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.285 (1.79% ) |
| Volume | 0.0013 mill |
| Avg. Vol. | 0.0563 mill |
| % of Avg. Vol | 2.33 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AMPE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AMPE
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Latest Press Releases
2024-04-03 14:33:00 - Press Release
Ampio Pharmaceuticals Received Audit Opinion With Going Concern Explanation
Englewood, colo., april 3, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio") today announced that, as previously disclosed in its annual report on form 10-k for the year ended december 31, 2023, which was filed on march 27, 2024 with the securities and exchange commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the company's ability to continue as a going concern.
2024-03-25 17:00:00 - Press Release
Ampio Announces Voluntary Delisting And Sec Deregistration
Englewood, colo. , march 25, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio") today announced that its board of directors determined to voluntarily delist its common stock from the nyse american and deregister its common stock in order to terminate and suspend its reporting obligations under the securities and exchange act of 1934, as amended (the "exchange act").
2024-02-14 17:45:00 - Press Release
Ampio Provides Update On Results From Pre-ind Enabling Studies
Englewood, colo. , feb. 14, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced the efficacy results from recently completed nonclinical pre-ind enabling studies with oa-201, ampio's only product development opportunity.
2024-01-11 16:15:00 - Press Release
Ampio Provides Litigation Update - Reports Settlement In Principle Of Certain Pending Legal Actions
Englewood, colo. , jan. 11, 2024 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company" or "ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced that it has reached settlements in principle in the pending securities fraud class action, case number 22-cv-2105-wjm-meh (the "securities class action"), and the pending consolidated derivative actions in the united states district court for the district of colorado, case number 22-cv-2803-klm (the "consolidated derivative actions").
2023-10-31 09:00:00 - Press Release
Ampio Pharmaceuticals To Present At The Emerging Growth Conference
Englewood, colo. , oct. 31, 2023 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced that its ceo, michael a.
Latest News
2023-09-26 09:15:00 - PRNewsWire
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
ENGLEWOOD, Colo. , Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A.
2023-06-22 09:30:02 - InvestorPlace
3 Biotech Stocks to Buy With Explosive Upside Potential
The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.
2022-09-04 11:30:00 - PennyStocks
Which Strategies Are You Using With Penny Stocks in September?
Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
2022-04-22 16:20:25 - PennyStocks
Why These 3 Penny Stocks Are Climbing in Late April
Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-21 06:29:02 - Benzinga
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results. In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in.
2022-04-07 08:17:03 - Zacks Investment Research
New Strong Sell Stocks for April 7th
AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
2022-04-01 08:17:13 - Zacks Investment Research
New Strong Sell Stocks for April 1st
AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
2022-03-29 18:41:06 - Seeking Alpha
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
2022-03-24 09:41:02 - Benzinga
Why Ampio Pharmaceuticals Stock Is Rising Today
Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.
2021-12-14 13:49:05 - Zacks Investment Research
Ampio (AMPE) Upgraded to Buy: Here's What You Should Know
Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.